VEA
OMED

Virtus ETF Advisers’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Virtus ETF Advisers’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-36,113
Closed -$333K – 183
2017
Q1 		$333K Buy
36,113
+3,462
+11% +$30.4K 0.06% 128
2016
Q4 		$252K Buy
32,651
+12,382
+61% +$114K 0.08% 140
2016
Q3 		$232K Hold
20,269
– – 0.11% 128
2016
Q2 		$250K Buy
20,269
+7,900
+64% +$95.9K 0.19% 89
2016
Q1 		$125K Buy
+12,369
New +$145K 0.17% 134

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtus ETF Advisers's OMED Position: Q2 2017 in Review

Virtus ETF Advisers sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2017, closing a stake of 36,113 shares — an estimated $333K sold.

Virtus ETF Advisers first reported a position in OMED in Q1 2016 and held it in 5 quarters. The position peaked at $333K in Q1 2017. 68 funds tracked by Wall St. Rank hold OMED as of Q2 2017.

  • Virtus ETF Advisers reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Virtus ETF Advisers sold 36,113 OncoMed Pharmaceuticals, Inc. shares in Q2 2017, an estimated $333K.
  • Virtus ETF Advisers first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2016 and held it in 5 quarters.
  • Virtus ETF Advisers's OncoMed Pharmaceuticals, Inc. position peaked at $333K in Q1 2017.
  • 68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2017.

Based on Virtus ETF Advisers's 13F filing for Q2 2017, filed 14 Aug 2017.